Convergent Dental announced today that the US Food and Drug Administration (FDA) has cleared Solea, the first CO2 laser system for ablation of hard tissue for caries removal and cavity preparation. The FDA clearance news follows the company’s recent FDA clearance for soft tissue indications in February 2013. Today, Convergent Dental also announced the closing of Series A & B funding rounds totaling over $13.5 million.
Solea is a 9.3µm CO2 Computer Aided Preparation (CAP) dental laser system, which the company reports is the first on the market that uses pulsed energy, and other highly-advanced, patented technologies to safely and effectively cut hard tissue and perform incision, excision, vaporization, coagulation, and hemostasis of soft tissue in the oral cavity.
Back to News
